Critical Oncology Clinical Trial KPIs Under the 'New Normal'
Sponsored by: Scimega
- Clinical Trials
Date: 10 September
Time: 3PM London/10AM EST
How to Overcome COVID Challenges & Maximize the Opportunities
The COVID-19 pandemic has forced the clinical trial industry to adapt, adapt, adapt! The emerging ‘new normal’ means change, opportunity, and just as sponsors always have, the requirement for superior enrolment performance is as critical as ever.
Optimal operations design that is robust even in the face of this new reality must allow for innovative solutions devised specifically for each unique oncology clinical trial. Key in your response to the dynamic and evolving challenges is maximizing the learning curve for each opportunity that emerges. Further, Sponsors must rapidly reassess and determine where is the best region today for their trials given these new conditions.
The Critical Oncology Clinical Trial KPIs Under the ‘New Normal’ Webinar addresses:
• COVID challenges & opportunities for CRO performance
• Tips on how to score high on critical KPIs under the ‘new normal’
• Case examples of how to overcome COVID challenges & maximize the opportunities
• What you can achieve today by expanding your trial to Canada
Learn how to overcome COVID challenges & maximize the opportunities for your cutting-edge oncology clinical trial. Register today!
Julie Martin, M.Sc., MBA, Lean certified,
Director, Clinical Operations & Co-owner
Julie Martin, M.Sc., MBA, Lean certified Director, Clinical Operations & Co-owner of Scimega Research, a niche Canadian oncology CRO with a singular focus to promote and contribute to the successful conduct of cutting-edge oncology clinical trials in Canada. Her company has a proven track record of successful study conduct with 22 years of lessons learned.
Mrs. Martin has developed an expertise in managing a wide array of oncology clinical trials set in early and late clinical development stages including collaborative efforts with larger CROs. At Scimega she is responsible for the strategic planning, conduct and oversight of oncology clinical trials across Canada, and for the development of project proposals. In addition, Mrs. Martin serves as Director, Business Development, and is co-owner and an executive member of Scimega’s managing Board of Directors.
Patrick Smith, M.Sc.,,
Clinical Trial Leader
Patrick Smith, M.Sc., serves a dual role with Scimega Research. Through his responsibilities as Clinical Trial Leader, Patrick helps ensure the operational success of the cutting-edge oncology trials by small and mid-size biopharma companies Scimega attracts to Canada.
As Feasibility Manager Patrick connects an extensive collaborative Canadian network of top performing investigative sites with oncology biopharma trial sponsors who partner with Scimega. The program Patrick manages serves as a real-time notification system; a Canada-wide scan to identify recruitment opportunities as well as any existing competitive roadblocks, to provide an immediate and accurate assessment of Canada’s enrollment potential.
Patrick’s 13 years of clinical research experience includes his work with the Canadian Cancer Trials Group (CCGT). Patrick holds a Master of Science in Pathology and Molecular Medicine from Queen’s University, and is also a member of the American Society of Clinical Oncology (ASCO).
Key Learning Objectives
- Identify COVID challenges & opportunities for CRO performance
- Learn how to score high on critical KPIs under the ‘new normal’
- Acquire case example experiences of how to overcome COVID challenges & maximize the opportunities
- Discover what you can achieve today by expanding your trial to Canada
- SVP Clin Ops
- VP Clin Ops
- Exec Dir Clin Ops
- Sr Director Clin Ops
- Director Clin Ops
- VP Clin Development
- SVP Clin Development
- Exec Dir Clin Development
- Sr Director Clin Development
- Director Clin Development
- Exec Dir Med Affairs
- Sr Dir Med Affairs
- Director Medical Affairs
- Head Clin Ops
- Head Clin Development
- Head Med Affairs